Biofrontera (NASDAQ:BFRI – Get Free Report) and Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.
Insider & Institutional Ownership
10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Biofrontera and Inhibikase Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biofrontera | $41.71 million | 0.43 | -$10.54 million | ($0.45) | -2.69 |
| Inhibikase Therapeutics | $260,000.00 | 1,239.76 | -$48.26 million | ($0.43) | -5.37 |
Biofrontera has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Biofrontera and Inhibikase Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biofrontera | -13.78% | -145.81% | -31.30% |
| Inhibikase Therapeutics | N/A | -42.80% | -40.58% |
Analyst Recommendations
This is a breakdown of recent ratings for Biofrontera and Inhibikase Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biofrontera | 1 | 1 | 1 | 0 | 2.00 |
| Inhibikase Therapeutics | 1 | 1 | 4 | 3 | 3.00 |
Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 133.77%. Given Inhibikase Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Biofrontera.
Volatility and Risk
Biofrontera has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.
Summary
Inhibikase Therapeutics beats Biofrontera on 9 of the 15 factors compared between the two stocks.
About Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
